Results 271 to 280 of about 118,448 (336)

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Early clinical investigation of Viozan™ (sibenadet HCI), a novel D2 dopamine receptor, β2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms

, 2003
P.W. Ind, L. A. Laitinen, L. Laursen, Sally E. Wenzel, E.F.M. Wouters, L. Deamer, P O Nyström   +6 more
openalex   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Dopamine agonist-responsive Cushing's disease. [PDF]

BMJ Case Rep, 2019
Anand G, Bink A, Beuschlein F, Schmid C.
europepmc   +1 more source

Cannabidiol dose dependently reduces alcohol intake in mice via a non‐5‐HT1A receptor mechanism: Exploration of other potential receptor targets

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Binge drinking is a risky pattern of alcohol intake and a major predictor of alcohol use disorder (AUD). Current AUD medications have limited efficacy and poor patient compliance, calling for more effective therapeutics.
Connie J. Badolato, Erin A. Lynch, Jonathon C. Arnold, Iain S. McGregor, Michael T. Bowen   +4 more
wiley   +1 more source

Experimental Parkinsonism induced by tetanus toxin injected into basal ganglia

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Local inhibitory circuits and long‐range inhibitory projections within the interconnected basal ganglia nuclei are critical for control of voluntary movement and pathophysiology of different extrapyramidal movement disorders.
Patrik Meglić, Petra Šoštarić, Davor Virag, Ana Knezović, Nikola Habek, Ornella Rossetto, Ivica Matak   +6 more
wiley   +1 more source

Conclusion lessons from the novel D2 dopamine receptor, β2-adrenoceptor agonist, Viozan™: chronic obstructive pulmonary disease and drug development implications

, 2003
P. M. A. Calverley, E.T. Keating, Mitch Goldman, Frank E. Casty   +3 more
openalex   +1 more source

Dopamine D3 receptor blockade accelerates the extinction of opioid withdrawal‐induced drug‐seeking behaviours and alters microglia in dopaminoceptive nuclei

British Journal of Pharmacology, EarlyView.
Background and Purpose Among all drugs of abuse, opioids cause most of the deaths and treatment seeking. Despite abundant research in multifaceted therapeutic strategies, a high rate of relapse still characterises this condition. Dopamine D3 receptor antagonists combined with cue‐exposure therapies have been proposed to ameliorate the abused drugs ...
Aurelio Franco‐García, Victoria Gómez‐Murcia, M. Victoria Milanés, Cristina Núñez   +3 more
wiley   +1 more source